Largest biotechnology: biological products (no diagnostic substances) companies
Every US-listed biotechnology: biological products (no diagnostic substances) company we cover, 163 of them, ranked by market capitalisation, with revenue and earnings taken from their SEC filings.
Combined market cap
$935.673 B
1.0% of all US-listed value
Companies
163
Ranked #21 of 152 industries
Average
$5.740 B
Mean market cap per company
| # | Name | Market cap | Close | Session | Country |
|---|---|---|---|---|---|
| 1 | AmgenAMGN | $249.2B | $460.66 | -3.72% | United States |
| 2 | Gilead SciencesGILD | $207.8B | $167.53 | -3.98% | United States |
| 3 | ModernaMRNA | $96.5B | $241.79 | -6.42% | United States |
| 4 | Argenx SeARGX | $55.8B | $898.86 | -3.49% | Netherlands |
| 5 | Revolution MedicinesRVMD | $38.5B | $177.86 | -10.94% | United States |
| 6 | BiogenBIIB | $36.1B | $244.03 | -4.10% | United States |
| 7 | BioNTech SEBNTX | $21.6B | $86.01 | -5.18% | Germany |
| 8 | ExelixisEXEL | $16.8B | $68.70 | -5.57% | United States |
| 9 | Neurocrine BiosciencesNBIX | $16.2B | $160.29 | -3.47% | United States |
| 10 | Halozyme TherapeuticsHALO | $14.0B | $123.61 | -5.16% | United States |
| 11 | Bio-TechneTECH | $11.4B | $72.70 | -0.05% | United States |
| 12 | Kymera TherapeuticsKYMR | $10.8B | $126.95 | -6.83% | United States |
| 13 | RepligenRGEN | $10.8B | $168.39 | -5.50% | United States |
| 14 | QiagenQGEN | $10.5B | $50.87 | +0.07% | Netherlands |
| 15 | VaxcytePCVX | $9.84B | $62.18 | -5.33% | United States |
| 16 | Krystal BiotechKRYS | $8.92B | $300.86 | -3.21% | United States |
| 17 | ImmunityBioIBRX | $8.48B | $8.01 | -10.36% | United States |
| 18 | Twist BioscienceTWST | $7.95B | $119.94 | -15.88% | United States |
| 19 | ImmunovantIMVT | $5.87B | $28.44 | -4.90% | United States |
| 20 | CG OncologyCGON | $5.74B | $64.79 | -4.31% | United States |
| 21 | Kodiak SciencesKOD | $5.73B | $91.17 | -7.45% | United States |
| 22 | Scholar RockSRRK | $5.56B | $45.63 | -1.01% | United States |
| 23 | CRISPR TherapeuticsCRSP | $4.71B | $48.58 | -6.17% | Switzerland |
| 24 | Adaptive BiotechnologiesADPT | $4.35B | $26.85 | +0.51% | United States |
| 25 | Relay TherapeuticsRLAY | $3.76B | $17.01 | -5.66% | United States |
| 26 | Iovance BiotherapeuticsIOVA | $3.49B | $7.71 | -11.44% | United States |
| 27 | Tarsus PharmaceuticalsTARS | $3.33B | $67.59 | -2.15% | United States |
| 28 | Denali TherapeuticsDNLI | $3.16B | $19.75 | -5.80% | United States |
| 29 | Adma BiologicsADMA | $2.94B | $13.24 | +26.29% | United States |
| 30 | Beam TherapeuticsBEAM | $2.68B | $25.90 | -6.82% | United States |
| 31 | VericelVCEL | $2.65B | $51.77 | +13.83% | United States |
| 32 | Recursion PharmaceuticalsRXRX | $2.18B | $3.51 | -9.66% | United States |
| 33 | Hemab TherapeuticsCOAG | $2.13B | $45.61 | +1.15% | United States |
| 34 | Biocryst PharmaceuticalsBCRX | $1.95B | $7.59 | -7.89% | United States |
| 35 | Replimune GroupREPL | $1.90B | $20.03 | -3.19% | United States |
| 36 | Vir BiotechnologyVIR | $1.89B | $11.03 | -6.29% | United States |
| 37 | MesoblastMESO | $1.83B | $14.09 | -1.40% | Australia |
| 38 | Maze TherapeuticsMAZE | $1.80B | $32.47 | -2.73% | United States |
| 39 | AlvotechALVO | $1.78B | $4.56 | -2.35% | Luxembourg |
| 40 | NovavaxNVAX | $1.61B | $9.76 | -8.40% | United States |
| 41 | Lycia TherapeuticsLYCA | $1.50B | $28.86 | -0.21% | United States |
| 42 | ImmunocoreIMCR | $1.47B | $28.51 | -2.48% | United Kingdom |
| 43 | Taysha Gene TherapiesTSHA | $1.35B | $4.14 | -5.16% | United States |
| 44 | Inhibrx BiosciencesINBX | $1.18B | $80.00 | -7.79% | United States |
| 45 | Vor BiopharmaVOR | $1.15B | $18.69 | -7.11% | United States |
| 46 | ImmaticsIMTX | $930.0M | $6.22 | -10.06% | Germany |
| 47 | Odyssey TherapeuticsODTX | $904.9M | $18.83 | -3.46% | United States |
| 48 | Monte Rosa TherapeuticsGLUE | $872.8M | $10.23 | -5.45% | United States |
| 49 | MeiraGTxMGTX | $818.2M | $8.52 | -9.57% | United States |
| 50 | Prime MedicinePRME | $806.2M | $4.45 | -10.56% | United States |
| 51 | Cullinan TherapeuticsCGEM | $704.0M | $10.94 | -12.41% | United States |
| 52 | Sana BiotechnologySANA | $697.5M | $2.33 | -8.98% | United States |
| 53 | Solid BiosciencesSLDB | $686.4M | $6.15 | -5.67% | United States |
| 54 | Attovia TherapeuticsATTO | $684.1M | $14.99 | -3.94% | United States |
| 55 | Aura BiosciencesAURA | $659.6M | $6.36 | -4.36% | United States |
| 56 | Ginkgo BioworksDNA | $646.9M | $10.06 | -13.69% | United States |
| 57 | Bambusa TherapeuticsBBTX | $631.2M | $15.63 | -2.74% | United States |
| 58 | 4D Molecular TherapeuticsFDMT | $621.8M | $11.26 | -8.35% | United States |
| 59 | Candel TherapeuticsCADL | $615.6M | $8.05 | -11.11% | United States |
| 60 | DBV TechnologiesDBVT | $614.9M | $9.78 | -1.61% | France |
| 61 | Iambic TherapeuticsIAM | $550.1M | $11.61 | -13.40% | United States |
| 62 | Valneva SEVALN | $532.9M | $5.62 | -0.24% | France |
| 63 | Entera BioENTX | $521.8M | $3.00 | -3.54% | Israel |
| 64 | SurrozenSRZN | $517.4M | $29.07 | -8.15% | United States |
| 65 | SL ScienceSLBT | $504.7M | $0.90 | -18.92% | Taiwan |
| 66 | RegenxbioRGNX | $487.2M | $7.38 | -4.28% | United States |
| 67 | Electra TherapeuticsETRA | $449.4M | $7.16 | -10.16% | United States |
| 68 | Editas MedicineEDIT | $390.9M | $2.55 | -6.43% | United States |
| 69 | Tectonic TherapeuticTECX | $382.0M | $19.54 | -3.74% | United States |
| 70 | Allogene TherapeuticsALLO | $380.0M | $1.10 | -7.56% | United States |
| 71 | TevogenTVGN | $377.4M | $5.56 | -2.80% | United States |
| 72 | C4 TherapeuticsCCCC | $362.3M | $2.95 | -5.61% | United States |
| 73 | Zura BioZURA | $362.2M | $3.76 | -6.47% | Cayman Islands |
| 74 | TRex BioTRXB | $355.7M | $12.96 | -4.35% | United States |
| 75 | IRulya TherapeuticsIRLA | $335.1M | $30.91 | -2.40% | United States |
| 76 | Autolus TherapeuticsAUTL | $332.7M | $1.25 | -9.42% | United Kingdom |
| 77 | AgomAb TherapeuticsAGMB | $332.4M | $6.75 | -1.46% | Belgium |
| 78 | Fennec PharmaceuticalsFENC | $327.6M | $9.35 | -9.66% | United States |
| 79 | ProkidneyPROK | $322.0M | $1.07 | -4.91% | United States |
| 80 | Eikon TherapeuticsEIKN | $315.8M | $5.83 | -8.76% | United States |
| 81 | X4 PharmaceuticalsXFOR | $314.0M | $3.08 | -5.09% | United States |
| 82 | AlectorALEC | $310.6M | $2.10 | -8.11% | United States |
| 83 | Scribe TherapeuticsSCTX | $293.7M | $15.52 | -7.54% | United States |
| 84 | AgenusAGEN | $290.4M | $6.43 | -7.75% | United States |
| 85 | Kyverna TherapeuticsKYTX | $284.8M | $4.61 | -10.76% | United States |
| 86 | OcugenOCGN | $276.5M | $0.82 | -6.80% | United States |
| 87 | Precision BiosciencesDTIL | $274.7M | $9.84 | +21.12% | United States |
| 88 | Century TherapeuticsIPSC | $273.4M | $1.51 | -9.58% | United States |
| 89 | SAB BiotherapeuticsSABS | $266.6M | $2.93 | -7.86% | United States |
| 90 | Lineage Cell TherapeuticsLCTX | $247.3M | $0.98 | -5.07% | United States |
| 91 | Lexeo TherapeuticsLXEO | $239.6M | $2.92 | -9.60% | United States |
| 92 | Fate TherapeuticsFATE | $225.9M | $1.89 | -9.81% | United States |
| 93 | Cabaletta BioCABA | $214.5M | $1.27 | -10.91% | United States |
| 94 | Protalix BioTherapeuticsPLX | $202.6M | $2.52 | -6.51% | Israel |
| 95 | Artiva BiotherapeuticsARTV | $202.4M | $4.14 | -1.90% | United States |
| 96 | Palisade BioPALI | $202.2M | $1.16 | -7.20% | United States |
| 97 | Inhibikase TherapeuticsIKT | $201.6M | $1.45 | -7.67% | United States |
| 98 | CompugenCGEN | $183.0M | $1.94 | -4.68% | Israel |
| 99 | InvivydIVVD | $171.6M | $0.58 | -8.10% | United States |
| 100 | Innate PharmaIPHA | $156.4M | $1.40 | +0.71% | France |
Showing 1–100 of 163 companies. One row per company, with secondary share classes folded into their primary listing.
Sectors biotechnology: biological products (no diagnostic substances) companies sit in
Other industries
Semiconductors 100Computer Software: Prepackaged Software 232Computer Software: Programming Data Processing 77Computer Manufacturing 10Biotechnology: Pharmaceutical Preparations 498Major Banks 244Catalog/Specialty Distribution 30Industrial Machinery/Components 210Business Services 90Commercial Banks 35Auto Manufacturing 29Integrated oil Companies 16Department/Specialty Retail Stores 13Real Estate Investment Trusts 173Investment Bankers/Brokers/Service 69Oil & Gas Production 116Beverages (Production/Distribution) 36Telecommunications Equipment 84Electric Utilities: Central 61Finance: Consumer Services 164Medical Specialities 44Consumer Electronics/Appliances 23Property-Casualty Insurers 68Natural Gas Distribution 27All industries →
Figures come from SEC filings and daily market prices. Companies listed only outside the US are not covered: see methodology.